Back to Report Store Home

Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 – Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market

  • Published: Dec-2018
  • Report Code: GBIHC487MR
  • Report Format: pdf


Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant proportion of these people are progressing to NASH. The disease is more frequently progressive and may lead to cirrhosis with complications of hepatocellular carcinoma, liver failure and liver-related death or the requirement of liver transplantation, which is not always feasible. NASH is a major global healthcare problem as the number of NASH patients is increasing. NASH has been gradually rising in the Asia-Pacific region, owing to the growing prevalence of diabetes, obesity and metabolic syndromes, an aging population and increasingly Westernized lifestyles. Increasing risk factors will result in more people living with the condition and drive revenue growth. Patients with NAFLD and NASH are at increased risk of mortality as well as liver, cardiovascular and malignancy-related death. The poor long-term prognosis associated with NASH in particular has created a pressing need for improved therapeutic options. At present, there is no approved drug to treat NASH. Lifestyle modification is the initial approach to managing patients with NASH, and then pharmacological treatments such as vitamin E and pioglitazone are recommended as first-line drugs for biopsy-proven NASH. Significant unmet need exists for NASH-specific products that can treat patients with the condition. NASH-specific therapies, namely selonsertib, elafibranor, Ocaliva and saroglitazar, are in the pipeline for NASH.


  • The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.

  • How will the approval of NASH-specific therapies affect the market?

  • The NASH market has cheap, generic, off-label drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the NASH market?

  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

  • How will changes in risk factors such as population age, obesity, type 2 diabetes, NAFLD, metabolic syndrome and lifestyle influence the market?

  • The pipeline for NASH therapies is quite diverse with a range of molecule types and molecular targets.

  • Which molecular targets appear most frequently in the pipeline?

  • How have the late-stage therapies performed in clinical trials?

  • The level of unmet need in the NASH market is significantly high. Will the pipeline drugs fulfill these unmet needs?

  • Various drivers and barriers will influence the market over the forecast period.

  • Licensing deals are the most common form of strategic alliance in NASH, with total deal values ranging from under $10m to over $300m.

  • How do deal frequency and value compare between target families and molecule types?

  • What were the terms and conditions of key licensing deals?

Reasons To Buy

  • This report will enable you to:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

  • Visualize the composition of the NASH market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

  • Analyze the NASH pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

  • Predict NASH market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

  • Identify commercial opportunities in the NASH deals landscape by analyzing trends in licensing and co-development deals.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments